Downregulation of TGFβ isoforms and their receptors contributes to keratinocyte hyperproliferation in psoriasis vulgaris

Journal of Dermatological Science

Volumn 33, Issue 1, 2003, Pages 7-16

  Doi, Hisao ^a   Shibata, Masa Aki ^a   Kiyokane, Kimihiro ^a   Otsuki, Yoshinori ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

A dominant negative TGF type II receptor; Psoriasis; TGF ; TGF receptors

Indexed keywords

BROXURIDINE; CYCLINE; MESSENGER RNA; MUTANT PROTEIN; RECEPTOR SUBTYPE; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA1 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA2 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA3; TRANSFORMING GROWTH FACTOR BETA3 RECEPTOR; UNCLASSIFIED DRUG; ISOPROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ADULT; AGED; ARTICLE; CELL MUTANT; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; DNA SYNTHESIS; DNA VECTOR; DOWN REGULATION; EPITHELIUM CELL; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KERATINOCYTE; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PSORIASIS VULGARIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN EPITHELIUM; CASE CONTROL STUDY; CELL DIVISION; DOMINANT GENE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PSORIASIS; SKIN;

ADULT; AGED; CASE-CONTROL STUDIES; CELL DIVISION; DOWN-REGULATION; GENES, DOMINANT; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; MIDDLE AGED; PROTEIN ISOFORMS; PSORIASIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0141758371     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-1811(03)00107-5     Document Type: Article

References (30)

1. Christophers E., Sterry W., Psoriasis. In: Fitzpatrick T.B., Aizen A.Z., Wolff K., Freedberg I.M., Austen K.F. 4th ed Dermatology in general medicine. 1:1993;489-514 McGraw-Hill, New York.
2. Roberts A.B., Sporn M.B. Physiological actions and clinical applications of transforming growth factor-β (TGFβ). Growth Factors. 8:1993;1-9.
3. Shipley G.D., Pittelkow M.R., Wille J.J., Scott R.E., Moses H.L. Reversible inhibition of normal human prokeratinocyte proliferation by type β transforming growth factor-growth inhibitor in serum-free medium. Cancer Res. 46:1986;2068-2071.
4. Border W.A., Ruoslahti E. Transforming growth factor-β in disease: the dark side of tissue repair. J. Clin. Invest. 90:1992;1-7.
5. Lyons R.M., Moses H.L. Transforming growth factors and the regulation of cell proliferation. Eur. J. Biochem. 187:1990;467-473.
6. Massagué J. The transforming growth factor-β family. Annu. Rev. Cell Biol. 6:1990;597-641.
7. Wataya-Kaneda M., Hashimoto K., Kato M., Miyazono K., Yoshikawa K. Differential localization of TGF-β-precursor isotypes in psoriatic human skin. J. Dermatol. Sci. 11:1996;183-188.
8. Lawrence D.A. Transforming growth factor-β: a general review. Eur. Cytokine Netw. 7:1996;363-374.
9. Massagué J. TGFβ signaling: receptors, transducers, and mad proteins. Cell. 85:1996;947-950.
10. Wrana J.L., Attisano L., Wieser R., Ventura F., Massagué J. Mechanism of activation of the TGF-β receptor. Nature. 370:1994;341-347.
11. Leivo T., Leivo I., Kariniemi A.L., Keski-Oja J., Virtanen I. Down-regulation of transforming growth factor-β receptors I and II is seen in lesional but not non-lesional psoriatic epidermis. Br. J. Dermatol. 138:1998;57-62.
12. Shibata M.A., Morimoto J., Otsuki Y. Suppression of murine mammary carcinoma growth and metastasis by HSVtk/GCV gene therapy using in vivo electroporation. Cancer Gene Ther. 9:2002;16-27.
13. Shibata M.A., Jorcyk C.L., Devor D.E., Yoshidome K., Rulong S., Resau J., Roche N., Roberts A.B., Ward J.M., Green J.E. Altered expression of transforming growth factor βs during urethral and bulbourethral gland tumor progression in transgenic mice carrying the androgen-responsive C3(1) 5′ flanking region fused to SV40 large T antigen. Carcinogenesis. 19:1998;195-205.
14. Böttinger E.P., Jakubczak J.L., Haines D.C., Bagnall K., Wakefield L.M. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res. 57:1997;5564-5570.
15. Ichijo H., Momose F., Miyazono K. Biological effects and binding properties of transforming growth factor-β on human oral squamous cell carcinoma cells. Exp. Cell Res. 187:1990;263-269.
16. Reiss M., Stash E.B. High frequency of resistance of human squamous carcinoma cells to the anti-proliferative action of transforming growth factor β Cancer Commun. 2:1990;363-369.
17. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., Fan R.S., Zborowska E., Kinzler K.W., Vogelstein B., Brattain M., Willson J.K. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science. 268:1995;1336-1338.
18. Takenoshita S., Tani M., Nagashima M., Hagiwara K., Bennett W.P., Yokota J., Harris C.C. Mutation analysis of coding sequences of the entire transforming growth factor beta type II receptor gene in sporadic human colon cancer using genomic DNA and intron primers. Oncogene. 14:1997;1255-1258.
19. Böttinger E.P., Jakubczak J.L., Roberts I.S.D., Mumy M., Hemmati P., Bagnall K., Merlino G., Wakefield L.M. Expression of a dominant-negative mutant TGF-β type II receptor in transgenic mice reveals essential roles for TGF-β in regulation of growth and differentiation in the exocrine pancreas. EMBO J. 16:1997;2621-2633.
20. Cui W., Fowlis D.J., Bryson S., Duffie E., Ireland H., Balmain A., Akhurst R.J. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell. 86:1996;531-542.
21. Iizuka H., Takahashi H. Psoriasis, involucrin, and protein kinase C. Int. J. Dermatol. 32:1993;333-338.
22. Wrone-Smith T., Mitra R.S., Thompson C.B., Jasty R., Castle V.P., Nickoloff B.J. Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am. J. Pathol. 151:1997;1321-1329.
23. Castelijns F.A., Gerritsen M.J., van Erp P.E., van de Kerkhof P.C. Cell-kinetic evidence for increased recruitment of cycling epidermal cells in psoriasis: the ratio histone and Ki-67 antigen expression is constant. Dermatology. 201:2000;105-110.
24. Segarini P.R., Rosen D.M., Seyedin S.M. Binding of transforming growth factor-β to cell surface proteins varies with cell type. Mol. Endocrinol. 3:1989;261-272.
25. Heldin C.H., Miyazono K., ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature. 390:1997;465-471.
26. Matsuura H., Myokai F., Arata J., Noji S., Taniguchi S. Expression of type II transforming growth factor-β receptor mRNA in human skin, as revealed by in situ hybridization. J. Dermatol. Sci. 8:1994;25-32.
27. Kane C.J.M., Knapp A.M., Mansbridge J.N., Hanawalt P.C. Transforming growth factor-β1 localization in normal and psoriatic epidermal keratinocytes in situ. J. Cell. Physiol. 144:1990;144-150.
28. Iavarone A., Massagué J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15. Nature. 387:1997;417-422.
29. Wieser R., Attisano L., Wrana J.L., Massagué J. Signaling activity of transforming growth factor β type II receptors lacking specific domains in the cytoplasmic region. Mol. Cell. Biol. 13:1993;7239-7247.
30. Chen R.-H., Ebner R., Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-β activities. Science. 260:1993;1335-1338.